These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 5539004)

  • 1. Variability of NPH insulin preparations.
    Belmonte MM; Colle E; DeBelle R; Murthy DY
    Can Med Assoc J; 1971 Jan; 104(2):133-8. PubMed ID: 5539004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of one daily injection of NPH and crystalline PZI insulins on urinary glucose in diabetic children.
    Mimouni M; Koivukangas T; Karp M; Laron Z
    Acta Diabetol Lat; 1979; 16(1):63-6. PubMed ID: 377878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term therapy with human insulin. Clinical experiences].
    Sachse G; Mäser E; Federlin K
    Dtsch Med Wochenschr; 1985 Mar; 110(11):403-6. PubMed ID: 3884307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Insulin combinations: improving the treatment of juvenile diabetes].
    Gúrpide Arraya N; Durá Travé T; Moya Benavent M
    Rev Enferm; 1997; 20(227-8):17-20. PubMed ID: 9282075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semilente-insulin at bedtime is superior to NPH-insulin for the suppression of the dawn-phenomenon in adolescents with type-I-diabetes.
    Holl RW; Teller WM; Heinze E
    Exp Clin Endocrinol Diabetes; 1996; 104(5):360-4. PubMed ID: 8957270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of glycaemic control in diabetic patients treated with morning or evening human ultratard insulin.
    Edsberg B; Dejgaard A; Kühl C
    Diabet Med; 1987; 4(1):53-5. PubMed ID: 2951221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical use of NPH insulin (author's transl)].
    Roesner M; Sauer H
    Dtsch Med Wochenschr; 1976 Jun; 101(23):886-9. PubMed ID: 1269430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting insulin analogs.
    Rosskamp RH; Park G
    Diabetes Care; 1999 Mar; 22 Suppl 2():B109-13. PubMed ID: 10097910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 1 diabetes mellitus: effective insulin strategies with less hypoglycemia.
    Bolli GB
    Postgrad Med; 2004 Nov; 116(5 Suppl Exploring):13-20. PubMed ID: 19667675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Insulin glargine improves fasting blood glucose levels in prepubertal children with unsatisfactorily controlled type 1 diabetes].
    Mianowska B; Szadkowska A; Czerniawska E; Pietrzak I; Bodalski J
    Pediatr Endocrinol Diabetes Metab; 2007; 13(4):189-93. PubMed ID: 18042313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the replacement of basal insulin in type 1 diabetes mellitus: no longer an elusive goal in the post-NPH era.
    Bolli GB; Andreoli AM; Lucidi P
    Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S43-52. PubMed ID: 21668336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative evaluation of the effectiveness of insulin preparations "Lente GP" and "Insulong" in type 1 diabetes mellitus].
    Kudriakova SV; Belovanova IM; Romanovskaia GA; Kasymov UA
    Sov Med; 1991; (9):75-7. PubMed ID: 1798933
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of insulin mixtures in type I diabetics: influence of the intermediate acting insulin on the action of short acting insulin.
    Goicolea I; Quiroga A; Vazquez JA
    Diabete Metab; 1987; 13(4):467-70. PubMed ID: 3315768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-acting insulin analogs: progressing slowly].
    Holleman F; Hoekstra JB
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
    Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
    Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of mixing human soluble and human crystalline zinc-suspension insulin: plasma insulin and blood glucose profiles after subcutaneous injection.
    Francis AJ; Hanning I; Alberti KG
    Diabet Med; 1985 May; 2(3):177-80. PubMed ID: 2952414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of type I diabetics with a combination of Superdep + DEP + NZI and an adjustment of the insulin dosage by means of a Biostator].
    Kábrt J; Masek Z; Páv J; Skrha J; Hodinár A
    Vnitr Lek; 1986 Apr; 32(4):373-8. PubMed ID: 3523974
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
    Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
    Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.